Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosome biogenesis protein BRX1 homolog is a ribosome assembly factor required for the synthesis of the large 60S ribosomal subunit. It is encoded by the BRIX1 gene and operates primarily in the nucleolus, supporting the final assembly steps needed to generate elongation-competent 80S ribosomes for protein synthesis[3][5]. BRIX1 is upregulated in several cancers, particularly colorectal cancer, and correlates with higher tumor stage and poorer patient survival[1]. Its expression may be a prognostic biomarker and a candidate for therapeutic intervention that targets the enhanced ribosome biogenesis in cancer cells[1].
Inhibition of ribosome biogenesis and protein synthesis (by drugs affecting RNA metabolism and ribosome assembly)
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosome biogenesis protein BRX1 homolog (BRIX1).